婴儿体外循环心脏手术中纤溶活性:FIBCON随机试验的前瞻性队列亚研究
结果显示体外循环后tPA-Ag、PAP和ROTEM ML显著升高,PAP每升高100 μg/l与平均失血量减少7.9%相关,补充纤维蛋白原浓缩物与PAP升高及ROTEM纤溶活性降低相关。
要点
- 体外循环后尽管使用氨甲环酸,tPA-Ag、PAP和ROTEM ML仍显著升高。
- PAP每升高100 μg/l与平均失血量减少7.9%相关。
- 补充纤维蛋白原浓缩物与PAP升高及ROTEM纤溶活性降低相关。
核心结论
- 婴儿体外循环心脏手术后纤溶系统被激活,表现为tPA-Ag和ROTEM ML升高。
- 补充纤维蛋白原浓缩物与PAP活性增加和临床出血减少相关。
研究设计与样本
- 前瞻性队列机制亚研究,嵌套于FIBCON随机对照试验,单中心三级儿童心脏手术和儿科重症监护病房。
主要发现
- 体外循环后tPA-Ag、PAP和ROTEM ML显著升高。
- tPA和PAP两种纤溶生物标志物相关(P=0.001),但均与ROTEM ML不相关。
- 术后早期失血量与PAP水平呈负相关,PAP每升高100 μg/l与平均失血量减少7.9%相关。
- 补充纤维蛋白原浓缩物未影响tPA-Ag,但与PAP水平升高和ROTEM纤溶活性降低有时序关联。
临床怎么用
- 婴儿体外循环心脏手术中常规使用氨甲环酸后仍可检测到纤溶激活,需关注术后纤溶相关出血。
- 纤维蛋白原浓缩物补充可能与PAP升高和临床出血减少相关,但需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibrinolytic activity contributes to bleeding after cardiopulmonary bypass (CPB). OBJECTIVE: Our objectives were, in a group of infants undergoing cardiac surgery with CPB: to document the extent of peri-operative fibrinolysis using rotational thromboelastometry (ROTEM) and standard biomarkers; to compare the agreement between these fibrinolytic measures; to assess whether fibrinolytic activity is associated with early postoperative mediastinal bleeding and assess whether supplementation with fibrinogen concentrate affected fibrinolysis. DESIGN: Prospective cohort, mechanistic substudy, nested within the FIBrinogen CONcentrate (FIBCON) randomised controlled trial. SETTING: Single centre, tertiary paediatric cardiac surgery and paediatric intensive care units. PATIENTS: Ninety infants (median age 6.3 months) undergoing cardiac surgery, who all received routine intra-operative tranexamic acid. The infants were randomised to receive either an individualised dose of fibrinogen concentrate ( n = 60) or placebo ( n = 30) during CPB. MAIN OUTCOME MEASURES: We measured the ROTEM variable maximum clot lysis (ML), and fibrinolytic biomarkers including plasmin-antiplasmin (PAP) and tissue plasminogen activator antigen (tPA-Ag). Blood was sampled pre-CPB, on-CPB and post-CPB, and 4 h after PICU admission. RESULTS: tPA-Ag, PAP and ROTEM ML increased significantly after CPB despite the use of tranexamic acid. The two fibrinolytic biomarkers t-PA and PAP, correlated ( P = 0.001) but neither correlated with ROTEM ML. Early postoperative blood loss was inversely associated with PAP levels. Each 100 μg l -1 rise in PAP was associated with a 7.9% reduction in mean blood loss. Fibrinogen concentrate supplementation as expected did not affect tPA-Ag but was temporally associated with an increase in PAP levels and a decrease in ROTEM fibrinolytic activity. CONCLUSION: Fibrinolysis is activated after paediatric cardiac CPB surgery as indicated by increased tPA-Ag and ROTEM ML. The substantial increase in tPA-Ag post-PICU admission is probably accompanied by a similar rise of plasminogen activator inhibitor 1 (PAI-1) as part of the acute phase response to surgery, thereby limiting clinical fibrinolysis. Supplementation of fibrinogen concentrate was associated with increased PAP activity and less clinical bleeding, consistent with the known role for fibrinogen in being a substrate for plasmin. TRIAL REGISTRATION: ISCTRN:50553029, Eudract:2013-003532-68.
引用
- Siemens K, Parmar K, Harris J, et al. Fibrinolytic activity in infants undergoing cardiac surgery on cardiopulmonary bypass with routine tranexamic acid: A prospective cohort substudy within the FIBrinogen CONcentrate randomised control trial. Eur J Anaesthesiol. 2025. PMID: 39895347. doi:10.1097/EJA.0000000000002124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。